@arsenalbio.com
We’re a clinical-stage programmable cell therapy company focused on realizing solid tumor cell therapies. Our purpose is clear: defeat cancer. Engineering Hope™ through living medicines designed to transform patient outcomes.
CEO Ken Drazan will join a panel tomorrow, March 4, 3:30-4:30pm, at #PMWC26 on Gene Editing & Synthetic Biology for Therapy.
More: https://bit.ly/40DVqfx #Biotech #DrugDevelopment #biosky
Today at the Evolution Summit, ArsenalBio’s Farah Anwar will share insights on CAR-T cell therapy and its potential to redefine the future of personalized cancer treatment.
More here: https://bit.ly/3LIZpn9 #cancer #cancerresearch #biosky
This Wednesday, ArsenalBio’s Farah Anwar will join a panel of clinical trial experts to share strategies for balancing scientific rigor, operational efficiency, and the patient experience.
More on the webinar: https://bit.ly/48Hyn7a #biosky #oncsky
Heading to Advanced Therapies USA 2025 this week? Check out one of the sessions where Christopher Murriel will share insights on #celltherapy development. http://bit.ly/3X1QJdU #biosky #oncsky
We’re gearing up for #SITC2025! We will share the latest research on our lead investigative cell therapy intended for mCRPC, CAR T cell therapy design, and our foundation model predicting targets for overcoming T cell exhaustion. Join us Nov 7–9: bit.ly/3JHY0wb @sitcancer.bsky.social
#CellTherapy
We’re presenting at the CAR-TCR Summit tomorrow on the development of our T cell therapy intended for metastatic prostate cancer and maintaining high potency in our development of cell therapy products. https://bit.ly/3KBpuDJ
#CellTherapy #CancerResearch #ProstateCancer
We’re developing a CAR-T cell therapy as a potential treatment for metastatic prostate cancer, for which new and more effective treatments are urgently needed. Stay tuned as we advance this program toward the clinic. More: https://bit.ly/3VqLxzg #ProstateCancer #CancerResearch #biosky #oncsky
Headshot of SOPHIA PHILLIPS of Arsenal Bio Process Development for Cell Therapies Summit Case Study: Overcoming Process Development Challenges in Solid Tumor-Targeting Cell Therapies Thursday, July 17, 2025 | 12:30pm ET | Boston SOPHIA PHILLIPS Scientist I Process Development
Join ArsenalBio scientist Sophia Phillips on July 17 at the Process Development for Cell Therapies Summit for a case study on overcoming process development challenges in solid tumor-targeting cell therapies.
Learn more at: bit.ly/3IuKGdF
#CellTherapy #DrugDevelopment #biosky
Hello, Bluesky! 👋
We’re ArsenalBio, a programmable, clinical-stage cell therapy company with one clear purpose: defeat cancer.
Follow us to explore the future of solid tumor therapies, cutting-edge CRISPR tech, and how we’re Engineering Hope™ for patients everywhere.
